# Evaluation Results

**Purpose**: Benchmark results, performance metrics, and evaluation reports

This directory contains **historical performance data** organized by development phase and methodology.

---

## Directory Structure

```
results/
├── phase1/         # Tier 1 Optimization (Days 1-7)
├── phase2/         # Comprehensive Evaluation (Days 8-10)
└── ensemble/       # Ensemble Method Validation
```

---

## Phase 1: Tier 1 Optimization (Days 1-7)

**Focus**: Initial model training and threshold optimization

**Goal**: Achieve ≥95% sensitivity and ≥90% specificity

### Documents

#### `phase1/TIER1_FINAL_RESULTS.md`
**Final Performance** (After all Tier 1 fixes):
- **Sensitivity**: 90.6% (target: ≥95%) ❌
- **Specificity**: 89.0% (target: ≥90%) ❌
- **Overall Accuracy**: 89.8%

**Key Finding**: Model hit synthetic data ceiling - ROC analysis proved no threshold can achieve both clinical targets simultaneously.

---

#### `phase1/TIER1_RESULTS_ANALYSIS.md`
**Root Cause Analysis**:
- Systematic bias toward Normal predictions
- 55.3% mean confidence on false negatives (≈ random guessing)
- 98.8% errors are systematic (80/81), not random noise
- Balanced training data → data imbalance NOT the cause

**Recommendations**:
1. Deeper architecture (more hidden layers)
2. Class-weighted loss (FocalLoss)
3. Better early stopping (G-mean metric)

---

#### `phase1/TIER1_FIXES_PROGRESS.md`
**Implementation Log** (Work in progress):
- ✅ Fix #1: Threshold optimization (0.40 threshold → 97.4% sensitivity, 77% specificity)
- ✅ Fix #2: FocalLoss + class weights (infrastructure complete)
- ⏳ Fix #3: DeepSNN architecture (design ready)

**Status**: Partial implementation, superseded by Phase 2 comprehensive approach

---

#### `phase1/TIER1_FIXES_COMPLETE.md`
**Final Implementation Summary**:
- All three fixes applied and trained
- Final model: DeepSNN + FocalLoss + G-mean early stopping
- Performance improvement: 88.2% → 90.6% sensitivity (+2.4%)

**Outcome**: Achieved best possible performance on synthetic data; ready for real data validation

---

## Phase 2: Comprehensive Evaluation (Days 8-10)

**Focus**: Full test set evaluation and real data preparation

**Goal**: Understand model limitations and prepare for MIT-BIH validation

### Documents

#### `phase2/PHASE2_EVALUATION_REPORT.md`
**Comprehensive Test Set Results** (1000 samples):
- **Overall Accuracy**: 89.5%
- **Sensitivity**: 90.6% ❌ (target: ≥95%)
- **Specificity**: 88.4% ✅ (target: ≥90%)
- **Mean Inference Time**: 267.4ms

**Detailed Analysis**:
- Confusion matrix breakdown
- Error confidence patterns
- Clinical metrics (PPV, NPV, F1)
- ROC curve analysis

**Critical Finding**: Model performance ceiling reached on synthetic data

---

#### `phase2/MITBIH_PREPROCESSING_RESULTS.md`
**MIT-BIH Data Preparation**:
- Dataset: 48 patients, ~109,000 heartbeats
- 5 arrhythmia classes (N, V, S, F, Q)
- Preprocessing pipeline validation
- Train/val/test split strategy

**Status**: 🚀 Data ready for Phase 8 training

---

## Ensemble: Variance Reduction Validation

**Focus**: Reducing prediction variance from stochastic Poisson encoding

**Problem**: Same input signal → different predictions (non-deterministic)

**Solution**: Ensemble averaging across multiple random seeds

### Documents

#### `ensemble/ENSEMBLE_TESTING_REPORT.md`
**Comprehensive Validation** (5 test suites, 100% pass rate):

**Performance**:
- **Variance Reduction**: 59% with N=5 ensemble runs
- **Inference Time**: <500ms for production config (N=3)
- **Accuracy**: Maintained (no degradation from averaging)

**Validation Tests**:
1. ✅ Variance reduction test (59% reduction)
2. ✅ Majority voting test (correct class aggregation)
3. ✅ Reproducibility test (deterministic with base_seed)
4. ✅ Performance test (<500ms, real-time capable)
5. ✅ Edge case test (handles corner cases)

**Recommendation**: Use N=3 for production (balance of variance reduction vs speed)

---

## Results Summary

### Overall Project Progress

| Phase | Model | Dataset | Sensitivity | Specificity | Accuracy |
|-------|-------|---------|-------------|-------------|----------|
| **Baseline** | SimpleSNN | Synthetic | 88.2% | 95.6% | 91.9% |
| **Phase 1** | DeepSNN | Synthetic | 90.6% | 89.0% | 89.8% |
| **Phase 2** | DeepSNN + Ensemble | Synthetic | 90.6% | 88.4% | 89.5% |
| **Phase 8** | TBD | MIT-BIH | 🚀 **TBD** | 🚀 **TBD** | 🚀 **TBD** |

### Key Achievements

- ✅ **Variance Reduction**: Ensemble averaging reduces prediction variance by 59%
- ✅ **Real-Time Inference**: <500ms with N=3 ensemble (clinical-grade)
- ✅ **Balanced Performance**: Improved sensitivity from 88.2% → 90.6%
- ⚠️ **Synthetic Ceiling**: Cannot exceed 90.6% sensitivity on current synthetic data

### Remaining Gaps

- ❌ **Sensitivity Target**: 90.6% < 95% (4.4% gap)
- ❌ **Specificity Target**: 88.4% < 90% (1.6% gap)
- 📋 **Real Data Validation**: Phase 8 required to validate clinical viability

---

## Using These Results

### For Performance Analysis

1. **Baseline comparison**: See `phase1/TIER1_FINAL_RESULTS.md`
2. **Error patterns**: See `phase1/TIER1_RESULTS_ANALYSIS.md`
3. **Latest metrics**: See `phase2/PHASE2_EVALUATION_REPORT.md`

### For Feature Validation

1. **Ensemble effectiveness**: See `ensemble/ENSEMBLE_TESTING_REPORT.md`
2. **Inference speed**: Check "Performance Test" section
3. **Variance reduction**: Check "Variance Reduction Test" section

### For Planning Next Steps

1. **Identify limitations**: See Phase 1 and Phase 2 critical findings
2. **Understand ceiling**: ROC analysis in `TIER1_RESULTS_ANALYSIS.md`
3. **Next milestone**: MIT-BIH validation (`phase2/MITBIH_PREPROCESSING_RESULTS.md`)

---

## Benchmark Comparison

### vs Problem Statement (PS.txt) Requirements

| Metric | Requirement | Current | Status |
|--------|-------------|---------|--------|
| Accuracy | ≥92% | 89.5% | ❌ -2.5% |
| Sensitivity | ≥95% | 90.6% | ❌ -4.4% |
| Specificity | ≥90% | 88.4% | ❌ -1.6% |
| Inference Time | <50ms | 267ms | ❌ +217ms |
| Energy Efficiency | 60%+ vs CNN | 🚧 Not measured | ⏸️ Pending |

**Status**: 0/5 targets met on synthetic data

**Next Steps**: Phase 8 MIT-BIH validation to measure real-world performance

---

### vs Industry Benchmarks (MIT-BIH)

| Study | Model | Sensitivity | Specificity | Classes |
|-------|-------|-------------|-------------|---------|
| **CortexCore (Current)** | DeepSNN | 90.6% | 88.4% | 2 |
| Benchmark Study 1 | CNN | 98.5% | 96.2% | 5 |
| Benchmark Study 2 | LSTM | 97.1% | 94.8% | 5 |
| Benchmark Study 3 | Ensemble | 99.2% | 98.1% | 5 |

**Gap Analysis**:
- Need +6.5% sensitivity to match industry (90.6% → 97.1%)
- Need +8.6% specificity to match industry (88.4% → 97.0%)
- Currently binary (2 classes), need multi-class (5 classes)

---

## Data Quality Notes

### Synthetic Data Characteristics

**Strengths**:
- ✅ Perfect labels (no annotation errors)
- ✅ Controlled variability
- ✅ Fast generation (no data acquisition delays)
- ✅ Balanced classes (50/50 split)

**Limitations**:
- ❌ Limited morphology variability (only 2 BPM settings)
- ❌ Clean signals (SNR > 30dB vs real 15-25dB)
- ❌ No patient-specific characteristics
- ❌ No real-world artifacts (motion, electrode noise)
- ❌ Fixed parameters (doesn't capture population diversity)

**Conclusion**: Synthetic data useful for MVP, but real data required for clinical validation

---

## Future Evaluation Plans

### Phase 8: MIT-BIH Real Data

**Planned Metrics**:
- 5-class arrhythmia detection accuracy
- Per-class sensitivity and specificity
- Confusion matrix analysis
- Comparison with published benchmarks

**Deliverable**: `results/phase8/MITBIH_REAL_DATA_RESULTS.md`

---

### Phase 10: STDP Implementation

**Planned Metrics**:
- STDP vs backprop accuracy comparison
- Hybrid model performance (STDP layer 1 + backprop layer 2)
- Training time comparison
- Biological plausibility validation

**Deliverable**: `results/phase10/STDP_EVALUATION.md`

---

## Related Documentation

- **Planning**: `/docs/planning/` - Why these evaluations were prioritized
- **Implementation**: `/docs/implementation/` - How features were built
- **Guides**: `/docs/guides/` - How to run evaluations
- **Decisions**: `/docs/decisions/` - Technical choices based on results
